Why did AbbVie lower its 2026 profit forecast, and by how much?

AbbVie lowered its 2026 earnings forecast to account for the planned $10.9 billion acquisition of Apogee Therapeutics, expecting the deal to reduce full-year 2026 adjusted earnings by 14 cents per share; the new forecast is $13.87 to $14.07 per share, down from the prior range of $13.91 to $14.11 per share.

How did AbbVie’s second-quarter financial results compare to analyst expectations?

AbbVie reported adjusted earnings of $3.65 per share and revenue of $16.99 billion for the quarter ended June 30, both exceeding analyst estimates of $3.60 per share and $16.77 billion, respectively; meanwhile, Skyrizi sales rose 24.4% to $5.51 billion (vs. $5.45 billion expected), Rinvoq sales grew 24.5% to $2.53 billion (vs. $2.48 billion expected), and Humira sales fell 36% to $756 million (vs. $732.4 million expected).

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

Jul 31, 2026

AbbVie lowered its 2026 profit forecast to account for the $10.9 billion Apogee Therapeutics acquisition while beating Q2 earnings estimates on strong immunology drug sales.

reuters

2026-07-31

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

FAQ